Breaking Finance News

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Only yesterday Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) traded -1.97% lower at $17.43. The company’s 50-day moving average is $17.29 and its 200-day moving average is $14.97. The last closing price is up 16.46% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Trade Volume was down over the average, with 809,531 shares of LXRX changing hands under the typical 862,515

Zacks Investment Research has downgraded Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to Hold in a report released on 10/13/2016.

On 10/07/2016, HC Wainwright released a statement on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) increased the target price from $0.00 to $26.00 that indicated a possible upside of 0.41%.

See Chart Below

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. has 52 week low of $7.65 and a 52 week high of $19.62 and has a total market value of $0.

General Company Details For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *